Haryana stops production at plant making cough syrups flagged by WHO

Digital Desk: The Haryana government has halted all medicine production at a manufacturing factory connected to the World Health Organization study that up to 66 children in the Gambia may have died after having cough syrup made in India, which was released a week ago. At Maiden Pharmaceuticals' manufacturing facilities, the syrups' Haryana-based manufacturer, significant abnormalities have been discovered.

"Sonipat's pharmaceutical company sent samples of three of the WHO-recommended medications to the Central Drug Lab in Kolkata. Action would be taken after the reports are in, which are not yet in "however, a joint examination by the Central and Haryana state drug authorities discovered about 12 production problems, the Haryana Health Minister Anil Vij informed ANI.

In light of this, Mr. Vij added, "it has been decided that the entire manufacturing must be suspended."

According to a request for justification sent to the company, it was unable to provide a log book of the tools and equipment used to make and test the in-question medications.

There is no mention of the batch numbers of possibly harmful ingredients that were purchased for the production of cough syrups.

Propylene Glycol, Sorbitol Solution, and Sodium Methyl Paraben are some of the compounds.

The business did not validate the procedures and techniques used to make the aforementioned syrups.

A batch of propylene glycol that the company had previously analysed and deemed to be of "Standard Quality" turned out to be subpar in some ways.

The questioned cough syrups' in-process testing reports were not given to the investigators.

The dates when the product was approved and when it was manufactured differ.

The company has been given seven days to answer to the Haryana State Drugs Controller's show cause notice, after which the production licence may be suspended or revoked and additional legal action may be taken.